Outlook Therapeutics, Inc. (OTLK): Total Assets
$18.58M
As of 2025-09-30
$26.18M
As of 2026-06-30
-13.3%
3-year compound annual growth
-1.2%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-09-30 | $18.58M | -35.5% | 2025-12-19, Balance as of period end |
| 2024-09-30 | $28.82M | -10.8% | 2025-12-19, Balance as of period end |
| 2023-09-30 | $32.30M | +13.2% | 2024-12-27, Balance as of period end |
| 2022-09-30 | $28.53M | +25.1% | 2023-12-22, Balance as of period end |
| 2021-09-30 | $22.81M | +15.6% | 2022-12-29, Balance as of period end |
| 2020-09-30 | $19.73M | +15.2% | 2021-12-23, Balance as of period end |
| 2019-09-30 | $17.13M | -23.1% | 2020-12-23, Balance as of period end |
| 2018-09-30 | $22.28M | +7.5% | 2019-12-19, Balance as of period end |
| 2017-09-30 | $20.73M | -18.4% | 2018-12-18, Balance as of period end |
| 2016-09-30 | $25.41M | n/c | 2017-12-29, Balance as of period end |
| 2015-09-30 | $35.01M | n/a | 2016-12-29, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | 2025-09-30 | $18.58M | -35.5% |
| Scinai Immunotherapeutics Ltd. (SCNI) | 2025-12-31 | $11.63M | -13.5% |
| Inhibrx Biosciences, Inc. (INBX) | 2025-12-31 | $146.48M | -19.0% |
| Pluri Inc. (PLUR) | 2026-06-30 | $24.88M | -35.7% |
| Humacyte, Inc. (HUMA) | 2025-12-31 | $116.37M | -15.6% |
| Aligos Therapeutics, Inc. (ALGS) | 2025-12-31 | $88.53M | +26.3% |
| Prokidney Corp. (PROK) | 2025-12-31 | $335.57M | -23.9% |
| ImageneBio, Inc. (IMA) | 2025-12-31 | $152.98M | +860.8% |
| Dyadic International Inc (DYAI) | 2025-12-31 | $9.95M | +0.2% |
Compare OTLK, SCNI, INBX, PLUR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗